These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27268930)

  • 1. Stage of bladder cancer in Central Europe - Polish perspective.
    Poletajew S; Biernacki R; Buraczynski P; Chojnacki J; Czarniecki S; Gajewska D; Pohaba T; Sondka J; Skrzypczyk M; Suchojad T; Wojtkowiak D; Zaforemski B; Zapala L; Zemla A; Radziszewski P
    Neoplasma; 2016; 63(4):642-7. PubMed ID: 27268930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
    J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder.
    Bol MG; Baak JP; Buhr-Wildhagen S; Kruse AJ; Kjellevold KH; Janssen EA; Mestad O; Øgreid P
    J Urol; 2003 Apr; 169(4):1291-4. PubMed ID: 12629345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple adverse histological features increase the odds of under staging T1 bladder cancer.
    Weizer AZ; Wasco MJ; Wang R; Daignault S; Lee CT; Shah RB
    J Urol; 2009 Jul; 182(1):59-65; discussion 65. PubMed ID: 19447443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment delay and prognosis in invasive bladder cancer.
    Liedberg F; Anderson H; Månsson W
    J Urol; 2005 Nov; 174(5):1777-81; discussion 1781. PubMed ID: 16217282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radical cystectomy in the treatment of bladder cancer always in due time?].
    May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M
    Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
    May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
    Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
    Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.
    Kim KH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Urol Oncol; 2013 Nov; 31(8):1643-9. PubMed ID: 22591745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.